Friday, 16 October 2026European Markets

PROACTIS SA Stock Over 20% Down So Far Today

Loading stream...

(vianews) - shares of proactis sa (cac 40: proac.pa) fell by a staggering 20% to €0.08 at 11:07 est on wednesday, after five successive sessions in a row of losses. cac 40 is falling 0.47% to €7,335.58, after two successive sessions in a row of losses. this seems, up until now, a somewhat down trend trading session today.

proactis sa's last close was €0.10, 32.43% under its 52-week high of €0.15.

about proactis sa

proactis sa provides source-to-pay software solution. it operates software platform that will give control over business spend. it also offers procurement solutions that provide purchasing professionals with the tools they need for purchasing process for routine goods and services, capital goods, and major projects. in addition, it offers invoice capture services, system administration, supplier onboarding, and tail spent management services. further, its solutions integrate with various erp or financial systems. the company was formerly known as hubwoo and changed its name to proactis sa in january 2019. the company is based in suresnes, france. proactis sa operates as a subsidiary of proactis euro hedgeco limited.

earnings per share

as for profitability, proactis sa has a trailing twelve months eps of €-0.01.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.88%.

revenue growth

year-on-year quarterly revenue growth declined by 3.6%, now sitting on 14.11m for the twelve trailing months.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com